COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Protocol No
TRISHULA-TTX-030-002
Principal Investigator
Ben George
Phase
I
Summary
TTX-030 is protein that is a monoclonal antibody that affects a pathway on the surface of cells called the adenosine pathway, by inhibiting a protein called CD39. Cancer cells use the adenosine pathway to control the body’s immune system response and help cancer cells grow. By stopping CD39, TTX-030 changes the pathway and may help your immune system fight cancer cells. Budigalimab is a protein called a monoclonal antibody targeting PD-1; it aims to improve the immune response against cancer rather than targeting the tumor directly, allowing the body itself to fight the tumor. The FDA has approved the regimen of mFOLFOX6 or a chemotherapy agent docetaxel to treat various tumor types, including prostate, colon and stomach cancers. However, combination of TTX-030 and budigalimab, and/or mFOLFOX6 or docetaxel is an investigational use of the drugs.
Description
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL